Report: Sanofi has billion-dollar dengue opportunity in India

Sanofi Pasteur's India head Stephan Barth

Analysts have said Sanofi's ($SNY) dengue vaccine, once approved, could rake in €1 billion, or $1.31 billion, a year. But as the Business Standard reports, India alone is a billion-dollar opportunity. According to a report from Brandeis University, the number of cases in the country is almost 300 times higher than government figures. "Over recent months, we have seen a worrying increase in cases, putting a huge strain on health care systems," Stephan Barth, Sanofi Pasteur's India head, told the paper, noting that India is part of the company's global development strategy for the dengue vaccine. Story | Report